Efficiency of epilepsy treatment in the Moscow Region under the present-day conditions of drug provision
https://doi.org/10.14412/2074-2711-2015-3-10-14
Abstract
Objective: to evaluate the efficiency of epilepsy therapy in the two periods 2006–2007 and 2013–2014 due to drug provision-related changes: the use of antiepileptic drugs (AEDs) in accordance with their international nonproprietary name.
Patients and methods. The continuous sample survey enrolled patients aged 18 years and older, who had been seen by an epileptologist at the Moscow Regional Research Clinical Institute in 2006–2007 (n=1200) and 2013–2014 (n=1450). The patients who had received initial therapy (n=384) were divided into 2 groups in accordance with the type of drug provision. Group 1 (n=124) had recommended AEDs. In Group 2 (n=260), there was switching between AED analogues in 80% of the patients. Therapeutic efficiency was comparatively analyzed in relation to the AEDs used and treatment policies.
Results. In 2013–2014 versus 2006–2007, the rate of remissions and the number of respondents was halved. The analysis demonstrated significant differences (p<0.05) between Groups 1 and 2 in the following indicators: the number of respondents (75:52%), remission rates (58:38%), pharmacoresistance (25:47%), the frequency of use of brand (54:34%) and generic (45:65%) AEDs, and that of switching between AED analogues (0:80%).
About the Authors
Irina Gennadyevna Rudakova
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
61/2, Shchepkin St., Moscow 129110
Russian Federation
61/2, Shchepkin St., Moscow 129110
Yu. A. Belova
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
61/2, Shchepkin St., Moscow 129110
Russian Federation
61/2, Shchepkin St., Moscow 129110
References
1. Shorvon S. Handbook of epilepsy treatment. 3rd ed. Singapore: Wiley-Blackwell; 2010. P. 75-146.
2. Perucca E, Tompson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 2011 May;10(5):446-56. doi: 10.1016/S1474-4422(11)70047-3.
3. Мухин КЮ, Миронов МБ, Петрухин АС. Эпилептические синдромы. Диагностика и терапия. Руководство для врачей. Москва: Системные решения; 2014. 376 с. [Mukhin KYu, Mironov MB, Petrukhin AS. Epilepticheskiye sindromy. Diagnostika i terapiya. Rukovodstvo dlya vrachey [Epileptic syndromes. Diagnosis and therapy. A guide for physicians]. Moscow: Sistemniye resheniya; 2014. 376 p.]
4. Рудакова ИГ. Стартовая терапия эпилепсии у взрослых. Стратегия и тактика. Русский медицинский журнал. 2014;(18):147-51. [Rudakova IG. Starting therapy of epilepsy in adults. Strategy and tactics. Russkii meditsinskii zhurnal. 2014;(18):147-51. (In Russ.)].
5. Приказ Министерства здравоохранения Российской Федерации от 20 декабря 2012 г. № 1175н. «Об утверждении порядка назначения и выписывания лекарственных препаратов, а также рецептурных бланков на лекарственные препараты, порядка оформления указанных бланков, их учета и хранения». [Prikaz Ministerstva zdravookhraneniya Rossiiskoi Federatsii ot 20 dekabrya 2012 g. № 1175n. «Ob utverzhdenii poryadka naznacheniya i vypisyvaniya lekarstvennykh preparatov, a takzhe retsepturnykh blankov na lekarstvennye preparaty, poryadka oformleniya ukazannykh blankov, ikh ucheta i khraneniya». (In Russ.)].
6. Crawford P, Feely M, Guberman A, Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure. 2006 Apr;15(3): 165-76. Epub 2006 Feb 28.
7. Rudakova IG, Kotov AS, Belova YuA. Use of generic medicines in the treatment of epilepsy using Topiramate as an example. Neuroscience and behavioral physiology. Springer New York Consultants Bureau. 2012;42(6): 550-5.
8. Рудакова ИГ. Отдаленные результаты переключения на генериковые аналоги топирамата у больных эпилепсией. Эпилепсия и пароксизмальные состояния. 2013; 2):6-10. [Rudakova IG. Long-term results of switching to generique analogues of topiramate in patients with epilepsy. Epilepsiya i paroksizmal'nye sostoyaniya. 2013;(2):6-10. (In Russ.)].
9. Рекомендации экспертного совета Российской противоэпилептической лиги по применению оригинальных и воспроизведенных препаратов (дженериков) для лечения эпилепсии. Педиатрия 2011;90(3):75-6. [Recommendations of the expert Council of the Russian anti-epileptic League for use of original and generic drugs (generics) for the treatment of epilepsy. Pediatriya 2011; 90(3):75-6. (In Russ.)].
10. Карлов ВА, Власов ПН, Жидкова ИА. Предварительные результаты эффективности генерического леветирацетама (эпитера) в монотерапии у взрослых. Неврология, нейропсихиатрия, психосоматика. 2015;7(спецвыпуск 1):36-40. [Karlov VA, Vlasov PN, Zhidkova IA. Efficacy of generic levetiracetam (epiterra) in monotherapy for epilepsy in adult patients: preliminary results. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2015;7(S1):36-40. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2015-1S-36-40
11. Kramer G, Biraben A, Carreno M, et al. Current approaches to the use of generic antiepileptic drugs. Epilepsy Behav. 2007 Aug;11(1):46-52. Epub 2007 May 29.
12. World Health Organization (WHO). Global burden of epilepsy and need for a coordinated action an the country level to address its health, social and public knowledge implications. Resolution approved by the WHO Executive Board, http://apps.who.int/gb/ebwha/pdf_files/EB136/B136_R8-en.pdf
Review
For citations:
Rudakova I.G., Belova Yu.A. Efficiency of epilepsy treatment in the Moscow Region under the present-day conditions of drug provision. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(3):10-14. (In Russ.) https://doi.org/10.14412/2074-2711-2015-3-10-14
Views: 904
Email this article 